Blood test could tell doctors when to stop prostate cancer treatment early
NCT ID NCT07698535
First seen Jul 13, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study explores whether a simple blood test that measures tumor DNA (ctDNA) can help doctors decide when to stop a targeted radiation therapy called 177Lu-PSMA-617 in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if patients whose ctDNA levels do not drop after two cycles of treatment might benefit from switching therapies sooner rather than continuing a treatment that is not working. The trial involves about 64 participants and uses ctDNA testing along with standard scans to guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617, Pluvicto)
- What this could lead to
- If successful, this approach could help doctors personalize treatment duration, stopping therapy earlier in patients who are not responding and avoiding unnecessary side effects.
- What could go wrong
- This is a small Phase 2 study, so results may not apply to all patients. The ctDNA test may not reliably predict response, and early discontinuation could risk disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread